BiotechTube
Global Cancer Technology

Global Cancer Technology

San Diego, United States· Est.
globalcancertechnology.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

Global Cancer Technology is a private, pre-revenue biotech targeting high-unmet-need cancers, particularly glioblastoma multiforme (GBM). Its core technology involves small molecule inhibitors, notably GCT-007, which uniquely targets both PI3K and mTOR pathways to overcome resistance and modulate the tumor microenvironment. The company is in preclinical development, with ambitious goals to initiate Phase 1/2 trials by 2027, and is currently raising capital from accredited investors.

OncologyNeurology

Technology Platform

Platform centered on small molecule dual PI3K/mTOR inhibitors designed to cross the blood-brain barrier and overcome treatment resistance via autophagy inhibition. Also references a proprietary radioactivated nano-crystal drug transport technology.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

The significant unmet medical need in glioblastoma, a cancer with a very poor prognosis, represents a high-value market opportunity for any effective new therapy.
Success in GBM could also provide a pathway to treating brain metastases of other cancers and validate the platform for broader oncology applications.

Risk Factors

The company is at a very early, high-risk preclinical stage with no clinical data, facing a high likelihood of scientific failure.
It is entirely dependent on raising capital from investors in a competitive funding environment and operates in a crowded therapeutic area (PI3K/mTOR inhibition) with significant competition.

Competitive Landscape

GCT competes in the densely populated field of PI3K/AKT/mTOR pathway inhibitors, which includes large pharma and numerous biotechs. Its differentiation claims center on dual-pathway inhibition and BBB penetration for GBM, but it trails many companies with assets in later-stage clinical development for various cancers.

More companies in Oncology (General) →More companies in United States →